AbbVie has entered a clinical trial agreement with Bristol-Myers Squibb Company to evaluate the safety and efficacy of the former’s Rova-T, as well as in combination with the latter’s Opdivo, along with Opdivo + Yervoy regimen as a treatment for relapsed, extensive-stage, small-cell lung cancer (SCLC).

According to the agreement, phase I/II clinical programmes will be jointly conducted to explore the potential of the regimen and also to determine if the targeted cell killing and antigen release caused by Rova-T enhances the effect of immunotherapy.

Evolva SA and US National Institute of Allergy and Infectious Diseases (NIAID) have entered a co-development agreement to develop nootkatone in multiple formulations against mosquitoes that transmit the Zika virus.

Following the agreement, a study will be conducted at the Colorado State University and sponsored by NIH to test the repellency and insecticidal properties of nootkatone against mosquitoes infected with Zika virus.

The data from the study will supplement Evolva’s ongoing research and fulfil the US Environmental Protection Agency’s requirements to commercially launch nootkatone.

Trek Therapeutics plans to further develop its antiviral portfolio and antiviral drugs by acquiring the worldwide development and commercialisation rights to lomibuvir and merimepodib from Vertex Pharmaceuticals Incorporated.

According to the agreement, Vertex Pharmaceuticals will receive milestone and royalties payment from Trek Therapeutics based on the successful development and commercialisation of the drugs.

Cardiome Pharma has announced an underwritten public offering of its common stock shares.

“Cardiome Pharma has announced an underwritten public offering of its common stock shares.”

The company plans to invest the raised funds for the in-licensing of dalbavancin from Allergan plc and for milestone payments related to the drug, and for other general corporate purposes.

Leerink Partners LLC is acting as sole book running manager and Blake, Cassels & Graydon LLp is acting as the legal advisor for the offering.

Tricida INC plans to advance its late-stage trials on the first-in-class clinical candidate TRC101 for the treatment of patients with kidney disease by using the funds raised from a series C financing round.

The company has raised $55m from the financing round, which was led by Longitude Capital Management Co. along with vivo Capital LLC, Orbimed Advisors LLC, Sibling Capital ventures and Limulus Venture partners LP.

Image : AbbVie has entered a clinical trial agreement with Bristol-Myers Squibb Company. Photo : Courtesy of Sue Adair.